World Journal of Endocrine Surgery

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  15 (2023)
Volume  14 (2022)
Volume  13 (2021)
Volume  12 (2020)
Volume  11 (2019)
Volume  10 (2018)
Volume  9 (2017)
Volume  8 (2016)
Volume  7 (2015)
Volume  6 (2014)
Volume  5 (2013)
Volume  4 (2012)
Volume  3 (2011)
Volume  2 (2010)
Volume  1 (2009)
Related articles

VOLUME 4 , ISSUE 1 ( January-April, 2012 ) > List of Articles

EDITORIAL

Molecular Targeted Drugs for Advanced Thyroid Cancer

Hiroshi E Takami

Citation Information : Takami HE. Molecular Targeted Drugs for Advanced Thyroid Cancer. World J Endoc Surg 2012; 4 (1).

DOI: 10.5005/wjoes-4-1-v

License: CC BY-NC 4.0

Published Online: 01-04-2017

Copyright Statement:  Copyright © 2012; The Author(s).


Abstract
PDF Share
  1. Phase trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-19.
  2. Phase trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675-84.
  3. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161:923-31.
  4. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008;26:6025.
  5. Phase dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008;26:634s.
  6. Vandetanib for the treatment of patients with local advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28:767-72.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.